Guggenheim Reiterates Buy Rating for GeneDx Holdings Corp.
Guggenheim maintains a 'buy' rating on GeneDx Holdings Corp. with a $74 target, a 7.79% upside from the current price.
Key Points
- Guggenheim reiterated its 'buy' rating for GeneDx Holdings Corp. (WGS) on June 29, 2026, setting a price target of $74.
- Guggenheim's $74 price target implies 7.79% upside from GeneDx Holdings Corp.'s ($WGS) current $68.65 share price.
- Shares of GeneDx traded near $69.82 on Monday, with a market cap of about $2.07 billion and a forward P/E of 56.7.
- Recent insider activity included both buying and selling, while analysts like Piper Sandler and Canaccord Genuity also maintain 'buy' ratings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 29, 2026, Guggenheim reiterated its 'buy' rating for GeneDx Holdings Corp. (NasdaqGS: WGS), maintaining a price target of $74. This update comes as the company continues to be a focus for investors interested in the genomics sector.
GeneDx Holdings Corp. Stock Down 20.5%
Shares of NasdaqGS:WGS traded near $69.82 on Monday. GeneDx Holdings Corp. has a market capitalization of approximately $2.07 billion. The company shows a forward P/E ratio of 56.7 and a beta of 1.971, indicating higher volatility compared to the market. The stock has seen a 52-week low of $32.21 and a high of $170.87. Its 50-day moving average is $54.80, while the 200-day moving average stands at $97.77.
$WGS price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
GeneDx Holdings Corp. reported revenue of $442.7 million, with a growth rate of 17.4%. However, the company is not yet profitable, showing a net margin of -17.6% and a return on equity of -30.4%. The next earnings report is expected on July 28, 2026.
Insider Buying and Selling at GeneDx Holdings Corp.
Recent insider transactions at GeneDx Holdings Corp. included sales by Ryan Jason and Keith Meister of 3,576 shares each on June 18, 2026. On the same day, Joshua Ruch, Eli Casdin, and Thomas Fuchs each bought 4,248 shares, reflecting varied insider activity.
Analysts Set New Price Targets
On June 29, 2026, Guggenheim maintained its 'buy' rating for GeneDx Holdings Corp. with a $74 price target. Piper Sandler, on June 23, 2026, also maintained a 'buy' rating with a target of $63. Canaccord Genuity and Wells Fargo both kept their 'buy' ratings with targets of $75, as seen in reports from May 5, 2026. The consensus among analysts remains strong, with a mean target price of $78.44 and nine analysts offering opinions.
About GeneDx Holdings Corp.
GeneDx Holdings Corp., headquartered in Stamford, Connecticut, is a genomics company that provides genetic testing services, focusing on pediatric and rare disease diagnostics. The company specializes in whole exome and genome sequencing and also develops an AI-based platform for next-generation sequencing analysis. Founded in 2000, GeneDx employs about 1,300 people and is led by CEO Kevin Feeley.
Bottom Line
Guggenheim's reiteration of a 'buy' rating suggests continued confidence in GeneDx Holdings Corp.'s market potential, despite its current unprofitability. Investors keep an eye on 13F filings and analyst ratings for insights, but it's important to remember these are backward-looking indicators and may not reflect the company's current or future performance.
Get GeneDx Holdings Corp. alerts
New 13F filings, insider trades, and analyst moves on $WGS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.